Characterization of efficacy and safety of pathogen inactivated and quarantine plasma in routine use for treatment of acquired immune thrombotic thrombocytopenic purpura.
Fiche publication
Date publication
mai 2018
Journal
Vox sanguinis
Auteurs
Membres identifiés du Cancéropôle Est :
Dr FOHRER Cécile, Pr HERBRECHT Raoul, Dr OJEDA-URIBE Mario
Tous les auteurs :
Herbrecht R, Ojeda-Uribe M, Kientz D, Fohrer C, Bohbot A, Hinschberger O, Liu KL, Remy E, Ernst C, Lin JS, Corash L, Cazenave JP
Lien Pubmed
Résumé
Auto-immune thrombotic thrombocytopenic purpura (TTP) is a morbid multi-organ disorder. Cardiac involvement not recognized in initial disease descriptions is a major cause of morbidity. Therapeutic plasma exchange (TPE) requires exposure to multiple plasma donors with risk of transfusion-transmitted infection (TTI). Pathogen inactivation (PI) with amotosalen-UVA, the INTERCEPT Blood System for Plasma (IBSP) is licensed to reduce TTI risk.
Mots clés
cardiac diseases, infection, plasmapheresis, thrombotic thrombocytopenic purpura, transfusion medicine, transfusion reaction
Référence
Vox Sang.. 2018 May 21;: